How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?

Current Opinion in HIV and AIDS

Volumn 10, Issue 1, 2015, Pages 18-28

  Ananworanich, Jintanat ^a,b   Dubé, Karine ^c   Chomont, Nicolas ^d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

Acute HIV infection; Early antiretroviral therapy; HIV DNA; HIV reservoir; Replication competent virus

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOGLOBULIN M; ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TIME TO TREATMENT; VIRUS REPLICATION; ACUTE DISEASE; DISEASE CARRIER; DRUG ADMINISTRATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY; VIRUS LOAD;

ACUTE DISEASE; ANTI-RETROVIRAL AGENTS; DISEASE RESERVOIRS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 84918595374     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000122     Document Type: Review

References (45)

1. Finzi D (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science [internet]; [cited 23 July 2014]; 278: 1295-1300. http://www.sciencemag.org/cgi/doi/10.1126/science.278.5341.1295
2. Wong JK (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science [internet]; [cited 28 July 2014]; 278:1291-1295. http://www.sciencemag.org/cgi/doi/10.1126/science.278.5341.1291
3. Chun TW, Stuyver L, Mizell SB, et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A [internet]; 94:13193-13197. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24285&tool=pmcentrez&rendertype=Abstract.
4. Deeks SG, Autran B, Berkhout B, et al. (2012). Towards an HIV cure: a global scientific strategy. Nat Rev Immunol [internet]; Nature Publishing Group; [cited 25 January 2014]; 12:607-614. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3595991&tool=pmcentrez&rendertype=Abstract.
5. Deng K, Siliciano RF (2014). HIV: early treatment may not be early enough. Nature [internet]; [cited 23 July 2014]; 1-2. http://www.ncbi.nlm.nih.gov/pubmed/25043038.
6. Archin NM, Vaidya NK, Kuruc JD, et al. (2012). Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A [internet]; [cited 15 July 2014]; 109:9523-9528. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3386138&tool=pmcentrez&rendertype=Abstract.
7. Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV reservoir in long lived central memory CD4 T cells. Conference on Retroviruses and Opportunistic Infections; 2013.
8. Cheret A, Bacchus C, Melard A, et al. Early HAART in primary HIV infection protects TCD4 central memory cells and can induce HIV remission. Conference on Retroviruses and Opportunistic Infections [internet]; 2014. http://croi2014.org/sites/default/files/uploads/CROI2014-Final-Abstracts.pdf.
9. Persaud D, Gay H, Ziemniak C, et al. (2013). Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med [internet]; [cited 20 February 2014]; 369:1828-1835. http://www.ncbi.nlm.nih.gov/pubmed/24152233.
10. NIAID. 'Mississippi baby' now has detectable HIV, researchers find [internet]; 2014. http://www.niaid.nih.gov/news/newsreleases/2014/pages/mississippibabyhiv.aspx.
11. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. (2013). Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog [inter net]; [cited 22 February 2014]; 9:e1003211. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3597518&tool=pmcentrez&rendertype=Ab-stract.
12. Siliciano RF, Greene WC (2011). HIV latency. Cold Spring Harb Perspect Med [internet]; [cited 30 July 2014]; 1:a007096. http://www.pubmedcen-tral.nih.gov/articlerender.fcgi?artid=3234450&tool=pmcentrez&renderty-pe=Abstract.
13. Saleh S, Solomon A, Wightman F, et al. Brief report CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4 β T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110:1-3.
14. Evans V, Kumar N, Filali A, et al. (2013). Myeloid dendritic cells induce HIV-1 latency in nonproliferating CD4+ T cells. PLoS Pathog [internet]; [cited 16 August 2014]; 9:e1003799. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3855553&tool=pmcentrez&rendertype=Abstract.
15. Chun TW, Engel D, Berrey MM, et al. (1998). Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A [internet]; 95:8869-8873. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=21169&tool=pmcentrez&rendertype=Abstract.
16. Nishimura Y, Sadjadpour R, Mattapallil JJ, et al. (2009)High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc Natl Acad Sci U S A [internet]; 106:8015-8020. http://www.pubmedcentral.nih.gov/articleren-der.fcgi?artid=2683103&tool=pmcentrez&rendertype=Abstract.
17. Whitney JB, Hill AL, Sanisetty S, et al. (2014)Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature [internet]; Nature Publishing Group; [cited 21 July 2014]; http://www.nature.com/doifinder/10.1038/nature13594.
18. Okoye AA, Rohankhedkar M, Reyes M, et al. Early treatment in acute SIV infection limits the size and distribution of the viral reservoir. Conference on Retroviruses and Opportunistic Infections [internet]; 2014. http://croi2014.org/sites/default/files/uploads/CROI2014-Final-Abstracts.pdf.
19. Laguette N, Sobhian B, Casartelli N, et al. (2011). SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature [internet]; [cited 14 July 2014]; 474:654-657. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3595993&tool=pmcentrez&rendertype=Abstract.
20. Hrecka K, Hao C, Gierszewska M, et al. (2011). Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature [internet]; Nature Publishing Group; [cited 12 August 2014]; 474:658-661. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3179858&tool=pmcentrez&rendertype=Abstract.
21. Baldauf H-M, Pan X, Erikson E, et al. (2012). SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med [internet]; Nature Publishing Group; [cited 12 August 2014];18:1682-1687. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3828732&tool=pmcentrez&rendertype=Abstract.
22. Descours B, Cribier A, Chable-Bessia C, et al. (2012). SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology [internet]; 9:87. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3494655&tool=pmcentrez&rendertype=Abstract.
23. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
24. Chomont N, El-Far M, Ancuta P, et al. (2009). HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med [internet]; [cited 14 July 2014]; 15:893-900. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2859814&tool=pmcentrez&rendertype=Abstract.
25. Ananworanich J, Schuetz A, Vandergeeten C, et al. (2012). Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One [internet]; [cited 22 February 2014]; 7:e33948. http://www.pubmedcentral.nih.gov/articlerender.fcgi?ar-tid=3316511&tool=pmcentrez&rendertype=Abstract.
26. Josefsson L, Von Stockenstrom S, Faria NR, et al. (2013). The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A [internet]; [cited 30 July 2014]; 110:E4987-E4996. http://www.pubmedcentral.nih.gov/articler-ender.fcgi?artid=3870728&tool=pmcentrez&rendertype=Abstract.
27. Buzon MJ, Martin-Gayo E, Pereyra F, et al. (2014). Long-term antiretroviral treatment initiated in primary HIV-1 infection affects the size, composition and decay kinetics of the reservoir of HIV-1 infected CD4 T cells. J Virol [internet]; [cited 30 June 2014];(June). http://www.ncbi.nlm.nih.gov/pubmed/24965451.
28. Fiebig EW, Wright DJ, Rawal BD, et al. (2003). Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (London, England) [internet]; [cited 22 February 2014]; 17:1871-1879. http://www.ncbi.nlm.nih.gov/pubmed/12960819.
29. Chun T-W, Justement JS, Moir S, et al. (2007)Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis [internet]; [cited 28 July 2014]; 195:1762-1764. http://www.ncbi.nlm.nih.gov/pubmed/17492591.
30. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004; 78:1160-1168.
31. Appay V, Van Lier RAW, Sallusto F, Roederer M (2008). Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry. Part A: J Int Soc Anal Cytol [internet]; [cited 12 July 2014]; 73:975-983. http://www.ncbi.nlm.nih.gov/pubmed/18785267.
32. Sallusto F, Lenig D, Fo R, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials. Nature 1999; 401:708-712.
33. Descours B, Avettand-Fenoel V, Blanc C, et al. (2012). Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis [internet]; [cited 17 August 2014]; 54:1495-1503. http://www.ncbi.nlm.nih.gov/pubmed/22441653.
34. Gattinoni L, Lugli E, Ji Y, et al. (2011). A human memory T cell subset with stem cell-like properties. Nat Med [internet]; [cited 9 July 2014]; 17:1290-1297. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3192229&tool=pmcentrez&rendertype=Abstract.
35. Buzon MJ, Sun H, Li C, et al. (2014). HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med [internet]; [cited 9 July 2014]; 20:139-142. http://www.ncbi.nlm.nih.gov/pubmed/24412925.
36. Ananworanich J, Fletcher JLK, Pinyakorn S, et al. (2013). A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology [internet]; [cited 22 February 2014]; 10:56. http://www.pubmedcen-tral.nih.gov/articlerender.fcgi?artid=3669623&tool=pmcentrez&renderty-pe=Abstract.
37. Gianella S, Von Wyl V, Fischer M, et al. (2011). Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther [internet]; [cited 16 August 2014]; 16:535-545. http://www.ncbi.nlm.nih.gov/pubmed/21685541.
38. Goujard C, Girault I, Rouzioux C, et al. (2012). HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther [internet]; [cited 16 August 2014]; 17:1001-1009. http://www.ncbi.nlm.nih.gov/pubmed/22865544.
39. Hoen B, Cooper D, Lampe FC, et al. (2007). Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple anti-retroviral therapy: QUEST GW PROB3005. Clin Infect Dis [internet]; [cited 16 August 2014]; 45:381-390. http://www.ncbi.nlm.nih.gov/pubmed/17599319.
40. Jain V, Hartogensis W, Bacchetti P, et al. (2013). Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis [internet]; [cited 22 February 2014]; 208:1202-1211. http://www.ncbi.nlm.nih.gov/pubmed/23852127.
41. Koelsch KK, Boesecke C, McBride K, et al. (2011). Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS (London, England) [internet]; [cited 28 July 2014]; 25:2069-2078. http://www.ncbi.nlm.nih.gov/pubmed/21860347.
42. Markowitz M, Evering TH, Garmon D, et al. (2014). A randomized open-label study of 3-versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr (1999) [internet]; [cited 16 August 2014]; 66:140-147. http://www.ncbi.nlm.nih.gov/pubmed/24457632.
43. Ananworanich J, Vandergeeten C, Schuetz A, et al. HIV reservoir size and immunity in blood and sigmoid colon of acute HIV-infected Thai subjects following 5- and 3-drug HAART. Conference on Retroviruses and Opportunistic Infections. 2012.
44. Hare CB, Pappalardo BL, Busch MP, et al. (2006). Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis [internet]; 42:700-708. http://www.ncbi.nlm.nih.gov/pubmed/16447118.
45. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. (2014). Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS (London, England) [internet]; [cited 17 August 2014]; 28:1015-1020. http://www.ncbi.nlm.nih.gov/pubmed/24384692.